News | June 03, 2022
Mitsubishi Tanabe Pharma America presents 48-week results from phase 3 safety clinical study of Radicava ORS
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
he financing was significantly oversubscribed with high demand from both existing and new investors.
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
Nearly 6,000 patients have been treated with the drug since 2017
Subscribe To Our Newsletter & Stay Updated
